Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Kidney Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Breast Cancer, Familial 1

Interventions

pembrolizumab 43Nivolumab 29atezolizumab 11Specimen Handling 10Cyclophosphamide 10Bevacizumab 10Paclitaxel 9Magnetic Resonance Spectroscopy 9cabozantinib 7Ipilimumab 7Carboplatin 7fludarabine 6durvalumab 6avelumab 6Sunitinib 6Sorafenib 6Oxaliplatin 6Fluorouracil 6Docetaxel 6spartalizumab 5sargramostim 5Leucovorin 5Cisplatin 5Cetuximab 5aldesleukin 4Trastuzumab 4Radiosurgery 4Psychiatric Rehabilitation 4Irinotecan 4Gemcitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Health Promotion × Gastrointestinal × Clear all
NCT05056077 2026-06-02

TTBF

University of California, San Francisco

Phase NA Active not recruiting
353 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Kidney Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡